ESB-1609 / Escape Bio - LARVOL DELTA

A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5. (PubMed, Clin Pharmacol Drug Dev) - "ESB1609 crosses the blood-brain barrier with CSF:plasma ratios ranging between 0.04% and 0.07% across dose levels. ESB1609 demonstrated a favorable safety and tolerability profile at exposures expected to be efficacious."

Journal • P1 data • CNS Disorders

ESCAPE Bio Closes $73 Million in Crossover Financing to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration (Businesswire) - "ESCAPE Bio...today announced the closing of a $73M financing led by Wellington Management Company LLP....'The proceeds allow us to accelerate two programs into patients who lack disease modifying treatments.'"

Financing • CNS Disorders • Parkinson's Disease